Answers are grounded in this paper and cite their sources.
Breast cancer (BC) remains a leading cause of cancer-related morbidity and mortality among women worldwide, with treatment efficacy often limited by metastasis and therapeutic resistance. The MAPK pathway plays a pivotal role in BC progression by regulating cell proliferation, survival, and epithelial-mesenchymal transition. Dysregulation of this pathway contributes to tumor aggressiveness, chemoresistance, and poor prognosis, making it an attractive therapeutic target. This review comprehensively examines the role of the MAPK pathway in BC, evaluates current therapeutic strategies targeting this pathway, and discusses challenges and future directions in clinical translation through a systematic analysis of preclinical and clinical studies. Our analysis revealed that MAPK hyperactivation (particularly ERK and p38) is prevalent in HER2 + and triple-negative subtypes, driving proliferation and EMT through Twist1 and AP-1; MEK inhibitors and RAF inhibitors show partial clinical responses but face resistance via PI3K/AKT crosstalk; phytochemicals synergize with conventional therapies by modulating MAPK signaling; and ongoing clinical trials are exploring novel combinations with immunotherapy. Key limitations include toxicity (grade 3 rash in 25% of patients) and lack of predictive biomarkers. While MAPK targeting demonstrates therapeutic potential, overcoming resistance requires subtype-specific approaches. Future research should prioritize biomarker development for patient stratification, next-generation dual-pathway inhibitors, and rational combinations with immunotherapy. These strategies may improve outcomes in aggressive breast cancer subtypes.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: